No growth in revenue compared to H2 2021. Soaring expenses. Continued failure to execute on new products. Existing product runway facing imminent patent expiry. Incredibly overvalued.
- Forums
- ASX - By Stock
- Ann: 2022 Half Year Financial Results
No growth in revenue compared to H2 2021. Soaring expenses....
-
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NAN (ASX) to my watchlist
|
|||||
Last
$3.56 |
Change
0.120(3.49%) |
Mkt cap ! $1.078B |
Open | High | Low | Value | Volume |
$3.45 | $3.58 | $3.43 | $8.984M | 2.539M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 105140 | $3.55 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.56 | 6342 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 105140 | 3.550 |
1 | 1412 | 3.530 |
2 | 8760 | 3.510 |
2 | 7924 | 3.500 |
1 | 7760 | 3.490 |
Price($) | Vol. | No. |
---|---|---|
3.560 | 6342 | 5 |
3.570 | 16260 | 3 |
3.580 | 7760 | 1 |
3.590 | 11260 | 3 |
3.600 | 13735 | 6 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
NAN (ASX) Chart |